Challenges and opportunities for stem cell therapy in patients with chronic kidney disease

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations

Abstract

Chronic kidney disease (CKD) is a global health care burden affecting billions of individuals worldwide. The kidney has limited regenerative capacity from chronic insults, and for the most common causes of CKD, no effective treatment exists to prevent progression to end-stage kidney failure. Therefore, novel interventions, such as regenerative cell-based therapies, need to be developed for CKD. Given the risk of allosensitization, autologous transplantation of cells to boost regenerative potential is preferred. Therefore, verification of cell function and vitality in CKD patients is imperative. Two cell types have been most commonly applied in regenerative medicine. Endothelial progenitor cells contribute to neovasculogenesis primarily through paracrine angiogenic activity and partly by differentiation into mature endothelial cells in situ. Mesenchymal stem cells also exert paracrine effects, including proangiogenic, anti-inflammatory, and antifibrotic activity. However, in CKD, multiple factors may contribute to reduced cell function, including older age, coexisting cardiovascular disease, diabetes, chronic inflammatory states, and uremia, which may limit the effectiveness of an autologous cell-based therapy approach. This Review highlights current knowledge on stem and progenitor cell function and vitality, aspects of the uremic milieu that may serve as a barrier to therapy, and novel methods to improve stem cell function for potential transplantation.

Original languageEnglish (US)
Pages (from-to)767-778
Number of pages12
JournalKidney international
Volume89
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • end-stage renal disease
  • senescence
  • stem cells
  • uremia

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Challenges and opportunities for stem cell therapy in patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this